Peptides / Growth hormone axis

Modified form · 44 amino acids · 5,135.9 Da

Tesamorelin

ApprovedBanned in sport

Tesamorelin (Egrifta) is a synthetic GHRH analogue approved in the US to reduce excess belly fat in adults with HIV-related lipodystrophy. Studies in people tested it on body fat, weight and blood sugar, and it is banned in sport. PepBank shows 256 results on tesamorelin from 37 studies in people, and 32 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as TH 9507, TH-9507, TH9507, EGRIFTA, EGRIFTA SV, EGRIFTA WR and 1 more

Tesamorelin is also in 1 blend: tesamorelin + ipamorelin.

First 40 of 44 amino acids2 changed amino acids

Evidence level: Large trials in people256 of 288 results come from studies in people, including randomized trials.

Results in people

256

89% of 288 results

Results in animals

10% of 288 results

Results in lab cells

under 1% of 288 results

From computer models

0% of 288 results

Overview

Tesamorelin at a glance

What it is	Modified form, 44 amino acids
Approval	Approved in the US (Egrifta, 2010)
In sport	Banned in sport (WADA S2.2.4)
Studies	50 studies with results. 42 of them gave tesamorelin, with 288 results. 256 in people30 in animals2 in lab cells
Best study in people	Randomized controlled trial with 806 people (2010)
Clinical trials	23 registered: 3 active or planned, 9 with posted results
Community use	Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (labeled use); Visceral fat loss and body composition in people without HIV (off-label); Growth hormone optimization, with or without ipamorelin

The science

What is tesamorelin?

Approved growth hormone-releasing factor analogue for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Amino acids in one chain

The history of tesamorelin

2004
The oldest paper on tesamorelin in PepBank is from 2004.
2005June
A registered trial of tesamorelin started (NCT00123253).
2010November
FDA approved Egrifta for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.
2025March
FDA approved Egrifta WR for reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy.

Tesamorelin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 44 amino acidsFrom the first amino acid to the last

Y1A−DAI5FTNSY10+R+KVLG15QLSA+R20+KLLQ−D25IMS+RQ30QG−ESN35Q−E+RGA40+RA+RL

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Tesamorelin is a modified form of 44 amino acids, with no ring, 2 changed amino acids.

Formula

C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular weight

5,135.9 g/mol

CAS number

218949-48-5

Target

Growth hormone-releasing hormone receptor (gene GHRHR): agonistEvidence: approved-drug label

Development

Theratechnologies Inc. (Montreal). Secondary reports say CB Biotechnology, an affiliate of Future Pak, completed its acquisition of Theratechnologies on 2025-09-25; the FDA label of 2026-07-29 still names Theratechnologies Inc. as the manufacturer. Highest phase: past the trial stage (see status).

Identifiers

PubChem 16137828, ChEMBL CHEMBL1237026, UNII MQG94M5EEO, DrugBank DB08869, KEGG D06655, IUPHAR 6959

Full sequence, SMILES and InChIKey

Three-letter sequence
[(3E)-hex-3-enoyl]-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

InChIKey
QBEPNUQJQWDYKU-BMGKTWPMSA-N

SMILES
CC/C=C/CC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What tesamorelin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people256 of 288 results come from studies in people, including randomized trials.

Weight and appetite

66 results · 62 in people · 4 animal

In HIV-infected adults with abdominal fat, tesamorelin reduced belly (visceral) fat more than placebo over 6 months. JAMA, 2014

Top results

In HIV-infected adults with abdominal fat, tesamorelin reduced belly (visceral) fat more than placebo over 6 months. (JAMA, 2014)
In HIV patients with excess belly fat, tesamorelin reduced belly organ fat compared with placebo. (The Journal of clinical endocrinology and metabolism, 2010)
In adults with HIV and abdominal obesity, people who responded to tesamorelin had a larger rise in trunk muscle density than people on placebo. (The Journal of frailty & aging, 2019)

Immune system and inflammation

55 results · 55 in people

In HIV-infected patients with abdominal fat, tesamorelin lowered the clotting-related marker tPA more than placebo. AIDS, 2011

Top results

In HIV-infected patients with abdominal fat, tesamorelin lowered the clotting-related marker tPA more than placebo. (AIDS, 2011)
In people with HIV and fatty liver disease, tesamorelin lowered blood VEGFA compared with placebo. (Scientific reports, 2021)
In people with HIV and fatty liver disease, tesamorelin lowered blood markers of T-cell and monocyte activity compared with placebo. (Clinical infectious diseases, 2021)

Blood sugar

28 results · 25 in people · 3 animal

In adults with type 2 diabetes, tesamorelin did not change the insulin response to sugar compared with placebo. PloS one, 2017

Top results

In adults with type 2 diabetes, tesamorelin did not change the insulin response to sugar compared with placebo. (PloS one, 2017)
In rats on high-calorie diets given HIV drugs, tesamorelin reversed the insulin rise seen with the drugs alone. (PloS one, 2024)
In HIV-infected adults with abdominal fat, tesamorelin did not change blood glucose measures. (Journal of acquired immune deficiency syndromes, 2010)

Cholesterol and blood fats

22 results · 21 in people · 1 animal

In HIV patients with belly fat, tesamorelin lowered triglycerides while placebo patients had an increase. The New England journal of medicine, 2007

Top results

In HIV patients with belly fat, tesamorelin lowered triglycerides while placebo patients had an increase. (The New England journal of medicine, 2007)
In adults with type 2 diabetes, tesamorelin 2 mg lowered total cholesterol more than placebo did. (PloS one, 2017)
In HIV patients with excess belly fat, tesamorelin lowered triglycerides compared with placebo. (The Journal of clinical endocrinology and metabolism, 2010)

Growth hormone and growth

22 results · 19 in people · 3 animal

In HIV patients with belly fat, tesamorelin raised IGF-I levels while placebo patients had a small decrease. The New England journal of medicine, 2007

Top results

In HIV patients with belly fat, tesamorelin raised IGF-I levels while placebo patients had a small decrease. (The New England journal of medicine, 2007)
In HIV-infected adults with abdominal fat, tesamorelin raised IGF-I levels. (Journal of acquired immune deficiency syndromes, 2010)
In HIV-infected adults with belly fat gain, TH9507 1 mg daily raised IGF-I compared with placebo. (AIDS, 2005)

Liver

16 results · 14 in people · 2 animal

In people with HIV and fatty liver, tesamorelin lowered liver fat more than placebo did. The lancet. HIV, 2019

Top results

In people with HIV and fatty liver, tesamorelin lowered liver fat more than placebo did. (The lancet. HIV, 2019)
In people with HIV and fatty liver, tesamorelin raised liver activity of genes linked to a better liver cancer outlook. (JCI insight, 2020)
In HIV-infected adults with abdominal fat, tesamorelin reduced liver fat more than placebo over 6 months. (JAMA, 2014)

All 50 tesamorelin studies by area Open the Scientific page

Key tesamorelin studies

Studies in people come first, then studies in animals and in the lab.

People
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Falutz et al. 2010 · The Journal of clinical endocrinology and metabolism · 806 people · cited by 78
15 results
People
Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz et al. 2007 · The New England journal of medicine · 412 people · cited by 139
9 results
People
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Falutz et al. 2010 · Journal of acquired immune deficiency syndromes (1999) · 404 people · cited by 51
13 results
People
Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Ellis et al. 2025 · The Journal of infectious diseases · 73 people · cited by 2
4 results
People
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Stanley et al. 2019 · The lancet. HIV · 61 people · cited by 66
6 results

All 50 Tesamorelin studies

Tesamorelin clinical trials

ClinicalTrials.gov lists 23 trials of tesamorelin. 3 are active or planned, and 9 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Phase 3completed263 people

Body Composition and Adipose Tissue in HIV

Phase 4terminated6 planned

TH9507 in Patients With HIV-Associated Lipodystrophy

Phase 3completed412 people

All 13 Tesamorelin trials

Status and safety

Is tesamorelin approved?

FDA

United States

Approved

EGRIFTA, EGRIFTA SV, EGRIFTA WR, since 2010.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S2.2.4.

Yes. Approved in the US (Egrifta, 2010). The FDA label for Egrifta says: “Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy” No central EU authorisation (EMA). Banned in sport (WADA S2.2.4).

Laws and labels change, so check the regulator for the current status.

Tesamorelin side effects and safety

PepBank has 43 safety results from studies of tesamorelin. 34 of them come from studies in people.

Safety results from studies (43)

In adults with type 2 diabetes, tesamorelin did not change the insulin response to sugar compared with placebo. (PloS one, 2017)
In HIV-infected adults with abdominal fat, tesamorelin did not change blood glucose measures. (Journal of acquired immune deficiency syndromes, 2010)
In HIV patients with excess belly fat, tesamorelin was reported as generally well tolerated. (The Journal of clinical endocrinology and metabolism, 2010)
In HIV patients with belly fat, side effects did not differ significantly between tesamorelin and placebo. (The New England journal of medicine, 2007)
In people with HIV and fatty liver, tesamorelin did not change fasting blood sugar differently from placebo. (The lancet. HIV, 2019)
In HIV-infected adults with belly fat gain, TH9507 was reported as generally well tolerated. (AIDS, 2005)
In abdominally obese adults with low growth hormone, there were no serious side effects. (The Journal of clinical endocrinology and metabolism, 2012)
In older adults, mild side effects were reported by 68% of those given tesamorelin and 36% of those given placebo. (Archives of neurology, 2012)
In HIV patients with belly fat gain, tesamorelin was reported as generally well tolerated over the extension. (AIDS, 2008)
In people with HIV on integrase inhibitors, tesamorelin was well tolerated, with adverse events about as common as with placebo. (AIDS, 2024)
In adults with HIV-related fat redistribution, tesamorelin was linked to joint pain. (Obesity research & clinical practice, 2026)
In people with HIV and fat redistribution, tesamorelin was linked to side effects related to growth hormone. (Journal of the International Association of Providers of AIDS Care, 2026)
In a database of drug side-effect reports, carpal tunnel syndrome was reported much more often with tesamorelin than expected. This does not prove a cause. (Cureus, 2025)
In HIV patients with excess belly fat, blood glucose measures did not differ in a meaningful way between tesamorelin and placebo groups. (The Journal of clinical endocrinology and metabolism, 2010)
In HIV patients with belly fat, more patients on tesamorelin than on placebo left the study because of a side effect. (The New England journal of medicine, 2007)
In HIV patients with belly fat, blood glucose and insulin did not differ significantly between tesamorelin and placebo. (The New England journal of medicine, 2007)
In HIV-infected adults with abdominal fat, tesamorelin was reported as well tolerated. (Journal of acquired immune deficiency syndromes, 2010)
In people with HIV and fatty liver, tesamorelin did not change long-term blood sugar markers differently from placebo. (The lancet. HIV, 2019)
In people with HIV and fatty liver, injection site complaints were more common with tesamorelin than with placebo. (The lancet. HIV, 2019)
In people with HIV and fatty liver, none of the injection site complaints with tesamorelin were judged serious. (The lancet. HIV, 2019)
In HIV-infected adults with belly fat gain, TH9507 did not change blood glucose. (AIDS, 2005)
In abdominally obese adults with low growth hormone, side effects were similar with tesamorelin and with placebo. (The Journal of clinical endocrinology and metabolism, 2012)
In adults with type 2 diabetes, tesamorelin did not change fasting blood sugar compared with placebo. (PloS one, 2017)
In adults with type 2 diabetes, tesamorelin did not change long-term blood sugar compared with placebo. (PloS one, 2017)

See every safety result on the Scientific page

Doses studied (28 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
2 mg	Human	human	subcutaneous	26 weeks	Randomized trial in people · n = 806	Falutz 2010
2 mg	Human	human	subcutaneous	26 weeks	Randomized trial in people · n = 412	Falutz 2007
2 mg every day	Human	human	subcutaneous	6 months	Randomized trial in people · n = 404	Falutz 2010
2 mg daily	Human	human	subcutaneous	6 months	Randomized trial in people · n = 73	Ellis 2025
2 mg once daily	Human	human	Not reported	12 months	Randomized trial in people · n = 61	Stanley 2019
1 mg and 2 mg	Human	human	Not reported	12 weeks	Randomized trial in people · n = 53	Clemmons 2017
2 mg	Human	human	subcutaneous	6 months	Randomized trial in people · n = 48	Stanley 2014
1 mg	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 61	Falutz 2005
2 mg	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 61	Falutz 2005
2 mg daily	Human	human	subcutaneous	6 months	Randomized trial in people · n = 806	Mangili 2015
2 mg	Human	human	subcutaneous	26 weeks	Randomized trial in people · n = 410	Stanley 2011
1 mg/d	Human	human	subcutaneous	20 weeks	Randomized trial in people · n = 152	Baker 2012
1 and 2 mg	Human	human	subcutaneous	12 weeks	Randomized trial in people · n = 61	Falutz 2005
2 mg	Human	human	Not reported	12 months	Randomized trial in people · n = 60	Makimura 2012
2 mg daily	Human	human	Not reported	six months	Randomized trial in people · n = 50	Braun 2017
2 mg once daily	Human	human	Not reported	12 months	Randomized trial in people · n = 31	Russo 2024
1 mg/d	Human	human	subcutaneous	20 weeks	Randomized trial in people · n = 30	Friedman 2013
1 mg	Human	human	Not reported	10 weeks	Randomized trial in people · n = 22	Stewart 2026
2 mg	Human	human	s.c.	52 weeks	Randomized trial in people	Falutz 2008
2 mg	Human	human	Not reported	12 weeks	Randomized trial in people	Clemmons 2017
2 mg	Human	human	Not reported	7 days	Randomized trial in people	Teng 2013
2 mg	Human	human	Not reported	Not reported	Systematic review of studies	Ditta 2026
2 mg once daily	Human	human	subcutaneous	2 wk	Trial in people without random groups · n = 13	Stanley 2011
1 or 2 mg	Human	human	subcutaneous	14 days	Trial in people without random groups · n = 41	González-Sales 2015
2 mg daily	Human	human	Not reported	26 weeks	Observational study	Rahman 2020
1 or 2 mg daily	Human	human	subcutaneous	14 consecutive days	Other study type · n = 38	González-Sales 2015
up to 600 microg/kg	Animal	pig, rat and dog	intravenous or subcutaneous	daily repeat injections	Study in live animals	Ferdinandi 2007
approximately 375 microg/kg	Animal	dog	intratracheal dry powder insufflation	Not reported	Study in live animals	Jansen 2004

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

Tesamorelin is an approved prescription drug for excess belly fat in adults with HIV. Community sources describe off-label use for visceral fat loss at 1-2 mg once daily, often before bed.

Reported routines and cautions

What people use it for

Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (labeled use)S1 S2
Visceral fat loss and body composition in people without HIV (off-label)S3S4
Growth hormone optimization, with or without ipamorelinS3

Reported regimens

Regimens that community sources report for Tesamorelin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
EGRIFTA SV label: reduction of excess abdominal fat in HIV-infected adults with lipodystrophyOfficial label dosing of an approved product	subcutaneous injectioninto the abdomen, rotating sites	1.4 mg per dose	once daily	Not stated	label dose, not community practice	S1
EGRIFTA WR label: reduction of excess abdominal fat in HIV-infected adults with lipodystrophyOfficial label dosing of an approved product	subcutaneous injectioninto the abdomen, rotating sites	1.28 mg per dose	once daily	Not stated	label dose, not community practice	S2
Visceral fat reduction in people without HIV (off-label)	subcutaneous injectionS3: abdomen, before bed	1 to 2 mg per dose	once daily	12 to 26 weeks (S3); S4 names 8 to 12 weeks on and 4 weeks off as one cycling option	sources differ: 2 mg (S3) against 1-1.4 mg (S4). S3 calls 2 mg the FDA-approved dose, but the current labels give 1.4 mg and 1.28 mg. Both sources carry seller links.	S3S4
Stack with ipamorelin	subcutaneous injection	1 to 2 mg per dose of tesamorelin, with 200 mcg ipamorelin	once daily before bed	12 to 16 weeks	single source. The source carries seller links.	S3

Reported side effects

joint pain (arthralgia) and muscle pain (myalgia)S1 S2S4
injection-site redness and itchingS1 S2
pain in an arm or leg, and swelling in the limbs (peripheral edema)S1 S2
tingling (paresthesia)S4

Reported benefits (claims, not shown in trials)

less visceral fat, noticed from about 6 to 8 weeksS3
deeper sleep within 1 to 2 weeksS3

Cautions

The labels list warnings for increased risk of neoplasms, raised IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity and injection-site reactions.S1 S2
Both wikis report that visceral fat returns after the drug is stopped.S3S4
S3 reports that off-label use in people without HIV lacks robust clinical data, and that quality differs a lot between the approved product and research-grade or compounded product.S3
S4 reports a need to monitor blood sugar in people with pre-existing glucose intolerance, because growth hormone can work against insulin.S4

Status notes

Tesamorelin is FDA-approved as EGRIFTA SV (2 mg vial, 1.4 mg dose) and EGRIFTA WR (11.6 mg vial, 1.28 mg dose) for excess abdominal fat in HIV-infected adults with lipodystrophy.S1 S2
USADA lists tesamorelin as a non-Specified Substance, prohibited in sport at all times.S5

Community sources

S1EGRIFTA SV (tesamorelin) kit: prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EGRIFTA WR (tesamorelin) kit: prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S3Tesamorelin: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
S4Tesamorelin: The Only FDA-Approved GHRH Analogpeptidepedia.orgcarries seller links, not linked
S5Anthony McCauley Accepts Doping Sanction (opens in a new tab)usada.org

Gaps

No forum threads could be read (Reddit is blocked). The two community sources are wikis that compile other pages; S4 carries a vendor advertisement in its footer. Older labels (1 mg vial, 2 mg dose) are no longer on DailyMed, and S3 still cites the 2 mg figure as the approved dose. No community source gave a first-hand account. Cycling advice in S4 has no trial support, per S4.

Questions and more

Ask a question about tesamorelin

The answer links to every study it uses.

What does the evidence say about tesamorelin?Is tesamorelin tested in people?Compare with Hexarelin Compare with GHRP-6

Sources

Database: PepBank data for tesamorelin (data version 308560)
Regulator: FDA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about tesamorelin

Tesamorelin

ApprovedBanned in sport

Also known as TH 9507, TH-9507, TH9507, EGRIFTA, EGRIFTA SV, EGRIFTA WR and 1 more

What it is

Modified form, 44 amino acids

Approval

Approved in the US (Egrifta, 2010)

In sport

Banned in sport (WADA S2.2.4)

Studies

50 studies with results. 42 of them gave tesamorelin, with 288 results.
256 in people30 in animals2 in lab cells

Best study in people

Randomized controlled trial with 806 people (2010)

Clinical trials

23 registered: 3 active or planned, 9 with posted results

Community use

Reduction of excess abdominal fat in HIV-infected adults with lipodystrophy (labeled use); Visceral fat loss and body composition in people without HIV (off-label); Growth hormone optimization, with or without ipamorelin

Dose as reported

Class

Species

Route

Duration

Design

Source

2 mg

Human

human

subcutaneous

26 weeks

Randomized trial in people · n = 806

Falutz 2010

2 mg

Human

human

subcutaneous

26 weeks

Randomized trial in people · n = 412

Falutz 2007

2 mg every day

Human

human

subcutaneous

6 months

Randomized trial in people · n = 404

Falutz 2010

2 mg daily

Human

human

subcutaneous

6 months

Randomized trial in people · n = 73

Ellis 2025

2 mg once daily

Human

human

Not reported

12 months

Randomized trial in people · n = 61

Stanley 2019

1 mg and 2 mg

Human

human

Not reported

12 weeks

Randomized trial in people · n = 53

Clemmons 2017

2 mg

Human

human

subcutaneous

6 months

Randomized trial in people · n = 48

Stanley 2014

1 mg

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 61

Falutz 2005

2 mg

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 61

Falutz 2005

2 mg daily

Human

human

subcutaneous

6 months

Randomized trial in people · n = 806

Mangili 2015

2 mg

Human

human

subcutaneous

26 weeks

Randomized trial in people · n = 410

Stanley 2011

1 mg/d

Human

human

subcutaneous

20 weeks

Randomized trial in people · n = 152

Baker 2012

1 and 2 mg

Human

human

subcutaneous

12 weeks

Randomized trial in people · n = 61

Falutz 2005

2 mg

Human

human

Not reported

12 months

Randomized trial in people · n = 60

Makimura 2012

2 mg daily

Human

human

Not reported

six months

Randomized trial in people · n = 50

Braun 2017

2 mg once daily

Human

human

Not reported

12 months

Randomized trial in people · n = 31

Russo 2024

1 mg/d

Human

human

subcutaneous

20 weeks

Randomized trial in people · n = 30

Friedman 2013

1 mg

Human

human

Not reported

10 weeks

Randomized trial in people · n = 22

Stewart 2026

2 mg

Human

human

s.c.

52 weeks

Randomized trial in people

Falutz 2008

2 mg

Human

human

Not reported

12 weeks

Randomized trial in people

Clemmons 2017

2 mg

Human

human

Not reported

7 days

Randomized trial in people

Teng 2013

2 mg

Human

human

Not reported

Systematic review of studies

Ditta 2026

2 mg once daily

Human

human

subcutaneous

2 wk

Trial in people without random groups · n = 13

Stanley 2011

1 or 2 mg

Human

human

subcutaneous

14 days

Trial in people without random groups · n = 41

González-Sales 2015

2 mg daily

Human

human

Not reported

26 weeks

Observational study

Rahman 2020

1 or 2 mg daily

Human

human

subcutaneous

14 consecutive days

Other study type · n = 38

González-Sales 2015

up to 600 microg/kg

Animal

pig, rat and dog

intravenous or subcutaneous

daily repeat injections

Study in live animals

Ferdinandi 2007

approximately 375 microg/kg

Animal

dog

intratracheal dry powder insufflation

Not reported

Study in live animals

Jansen 2004

Context

Route

Amount

How often

How long

Agreement

Sources

EGRIFTA SV label: reduction of excess abdominal fat in HIV-infected adults with lipodystrophyOfficial label dosing of an approved product

subcutaneous injectioninto the abdomen, rotating sites

1.4 mg per dose

once daily

Not stated

label dose, not community practice

EGRIFTA WR label: reduction of excess abdominal fat in HIV-infected adults with lipodystrophyOfficial label dosing of an approved product

subcutaneous injectioninto the abdomen, rotating sites

1.28 mg per dose

once daily

Not stated

label dose, not community practice

Visceral fat reduction in people without HIV (off-label)

subcutaneous injectionS3: abdomen, before bed

1 to 2 mg per dose

once daily

12 to 26 weeks (S3); S4 names 8 to 12 weeks on and 4 weeks off as one cycling option

sources differ: 2 mg (S3) against 1-1.4 mg (S4). S3 calls 2 mg the FDA-approved dose, but the current labels give 1.4 mg and 1.28 mg. Both sources carry seller links.

S3S4

Stack with ipamorelin

subcutaneous injection

1 to 2 mg per dose of tesamorelin, with 200 mcg ipamorelin

once daily before bed

12 to 16 weeks

single source. The source carries seller links.

Tesamorelin

Tesamorelin at a glance

What is tesamorelin?

The history of tesamorelin

Tesamorelin structure and chemistry

What tesamorelin studies show

Weight and appetite

Immune system and inflammation

Blood sugar

Cholesterol and blood fats

Growth hormone and growth

Liver

Key tesamorelin studies

Tesamorelin clinical trials

Is tesamorelin approved?

Tesamorelin side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about tesamorelin

Related peptides

Tesamorelin vs sermorelin

Sources

Tesamorelin

Tesamorelin at a glance

What is tesamorelin?

The history of tesamorelin

Tesamorelin structure and chemistry

What tesamorelin studies show

Weight and appetite

Immune system and inflammation

Blood sugar

Cholesterol and blood fats

Growth hormone and growth

Liver

Key tesamorelin studies

Tesamorelin clinical trials

Is tesamorelin approved?

Tesamorelin side effects and safety

How people use it

What people use it for

Reported regimens

Reported side effects

Reported benefits (claims, not shown in trials)

Cautions

Status notes

Community sources

Ask a question about tesamorelin

Related peptides

Tesamorelin vs sermorelin

Sources